Oxford GlycoSciences submits Vevesca NDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Oxford GlycoSciences completes its rolling NDA submission for the type I Gaucher disease therapy Vevesca (OGT 918) Aug. 21. The submission for the oral glycolipid storage disorders agent, initiated in March, includes data on use of the drug as monotherapy as well as in combination with Genzyme's Cerezyme (imiglucerase). Results of an extension study with Vevesca monotherapy will be presented Sept. 22 at the European Society of Glycolipid Disorders workshop in the Netherlands
You may also be interested in...
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.